Can we use faecal calprotectin to distinguish abdominal pain of familial Mediterranean fever (FMF) from acute appendicitis?

2008 ◽  
Vol 28 (2) ◽  
pp. 239-240 ◽  
Author(s):  
Balahan Makay ◽  
Özer Makay ◽  
Erbil Ünsal
Keyword(s):  
Abdominal Pain ◽  
Familial Mediterranean Fever ◽  
Acute Appendicitis ◽  
Faecal Calprotectin ◽  
Mediterranean Fever

The significance of urinary beta-2 microglobulin level for differential diagnosis of familial Mediterranean fever and acute appendicitis

2016 ◽  
Vol 35 (7) ◽  
pp. 1669-1672 ◽  
Author(s):  
Yunus Ugan ◽  
Hakan Korkmaz ◽  
Atalay Dogru ◽  
Yavuz Savas Koca ◽  
Ayse Balkarlı ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Familial Mediterranean Fever ◽  
Acute Appendicitis ◽  
Mediterranean Fever ◽  
Beta 2 ◽  
Beta 2 Microglobulin

scholarly journals The evaluation of ENA-78 and fibrinogen levels for the differential diagnosis of familial Mediterranean fever and acute appendicitis

2019 ◽  
Vol 43 (3) ◽  
pp. 141-147
Author(s):  
Murat Güzel ◽  
Recep Aktimur ◽  
Kadir Yıldırım ◽  
Sude Hatun Aktimur ◽  
Mehmet Hakan Taşkın ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Familial Mediterranean Fever ◽  
Acute Appendicitis ◽  
Acute Peritonitis ◽  
Significant Difference ◽  
Mediterranean Fever ◽  
Group 2 ◽  
Wbc Count ◽  
Higher Sensitivity ◽  
Group 1

Abstract Background Familial Mediterranean fever (FMF) is a disorder mainly present in the Mediterranean region, characterized by abdominal attacks that mimic acute peritonitis. Therefore, FMF might be confused with other conditions presenting with acute abdominal pain, particularly acute appendicitis (AA). We aimed to evaluate whether epithelial-derived neutrophil-activating peptide-78 (ENA-78) and fibrinogen levels and white blood cell (WBC) counts could be used as potential markers in the differential diagnosis of acute FMF attacks and AA. Methods The study involved three groups: patients with AA who underwent surgery (group 1, n = 30), patients with FMF attacks (group 2, n = 30), and patients with FMF who were attack-free (n = 30, controls), which included patients who were diagnosed as having FMF previously but had no attacks for a month. Results Significant differences were detected in the ENA-78 and fibrinogen levels between group 1 and group 2. No significant difference was found in the WBC count between group 1 and group 2. It was concluded that the WBC count was more sensitive (66%) for group 1, and fibrinogen showed higher sensitivity (86%) and specificity (96%) for group 2 compared with the other parameters. Conclusions We suggest that AA can be distinguished in patients with signs of peritonitis who were diagnosed as having FMF previously with the use of ENA-78 and fibrinogen levels; fibrinogen and ENA-78 might be helpful in discriminating between FMF attacks and AA.

scholarly journals Familial Mediterranean Fever: an unusual cause of liver disease

2019 ◽  
Vol 45 (1) ◽  
Author(s):  
Maria Cristina Maggio ◽  
Maria Castiglia ◽  
Giovanni Corsello
Keyword(s):  
Abdominal Pain ◽  
Liver Disease ◽  
Familial Mediterranean Fever ◽  
Serum Amyloid A ◽  
Mefv Gene ◽  
Serum Amyloid ◽  
Aphthous Stomatitis ◽  
Homozygous Mutation ◽  
Amyloid A ◽  
Mediterranean Fever

Abstract Background Familial Mediterranean Fever is an autoinflammatory disease typically expressed with recurrent attacks of fever, serositis, aphthous stomatitis, rash. Only a few reports describe the association with hepatic involvement. Case presentation We describe the clinical case of a child affected, since the age of 1 year, by recurrent fever, aphthous stomatitis, rash, arthralgia, associated with abdominal pain, vomiting, lymphadenopathy. The diagnosis of Familial Mediterranean Fever was confirmed by the genetic study of MEFV gene; the homozygous mutation M694 V in exon was documented. A partial control of attacks was obtained with colchicine. The child continued to manifest only recurrent episodes of abdominal pain without fever, however serum amyloid A persisted high, in association with enhanced levels of CRP, AST and ALT (1.5 x n.v.). The dosage of colchicine was increased step by step and the patient achieved a better control of symptoms and biochemical parameters. However, the patient frequently needed an increase in the dose of colchicine, suggesting the possible usefulness of anti-interleukin-1 beta treatment. Conclusions The unusual presentation of Familial Mediterranean Fever with liver disease suggests the role of inflammasome in hepatic inflammation. Colchicine controls systemic inflammation in most of the patients; however, subclinical inflammation can persist in some of them and can manifest with increased levels of CRP, ESR, serum amyloid A also in attack-free intervals.

Incidence of familial Mediterranean fever (FMF) mutations among children of Mediterranean extraction with functional abdominal pain

2001 ◽  
Vol 138 (5) ◽  
pp. 759-762 ◽  
Author(s):  
Riva Brik ◽  
Dianna Litmanovitz ◽  
Drora Berkowitz ◽  
Raanan Shamir ◽  
Eldad Rosenthal ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Familial Mediterranean Fever ◽  
Functional Abdominal Pain ◽  
Mediterranean Fever

scholarly journals Familial Mediterranean Fever Complicated by a Triad of Adrenal Crisis: Amyloid Goiter and Cardiac Amyloidosis

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Sadi A. Abukhalaf ◽  
Beesan W. Dandis ◽  
Tasnim Za’tari ◽  
Adham M. Amro ◽  
Tareq Z. Alzughayyar ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Familial Mediterranean Fever ◽  
Cardiac Amyloidosis ◽  
Adrenal Crisis ◽  
Common Disease ◽  
High Morbidity ◽  
Aa Amyloidosis ◽  
Mediterranean Populations ◽  
Amyloid Goiter ◽  
Mediterranean Fever

Background. FMF is a common disease in the Mediterranean populations and may be complicated by AA amyloidosis. The coexistence of adrenal and thyroid amyloidosis in AA amyloidosis secondary to familial Mediterranean fever (FMF) is an extremely rare reported condition. We presented a previously unreported triad of adrenal, thyroid, and cardiac amyloidosis secondary to FMF. Presentation of Case. We reported a 23-year-old Palestinian male patient presented with hypotension, vomiting, diarrhea, and abdominal pain. The patient was subsequently diagnosed to have an adrenal crisis with both amyloid goiter and cardiac amyloidosis. Conclusion. It is crucial to recognize the adrenal crisis in patients with AA amyloidosis secondary to FMF who present similarly to acute FMF inflammatory episodes. The adrenal crisis has high morbidity and mortality, especially if not recognized early in the course of the disease.

Discontinuation of colchicine therapy in children with Familial Mediterranean Fever

2021 ◽  
pp. jrheum.201158
Author(s):  
Yonatan Butbul Aviel ◽  
Silman Rawan ◽  
Shafe Fahouma ◽  
Isaiah Wexler ◽  
Yackov Berkund
Keyword(s):  
Abdominal Pain ◽  
Familial Mediterranean Fever ◽  
Pediatric Patients ◽  
Predictors Of Success ◽  
Successful Termination ◽  
Select Group ◽  
Mediterranean Fever ◽  
Colchicine Therapy

Objective Colchicine has been considered a life-long therapy for Familial Mediterranean fever (FMF). Recent studies describe patients who discontinued colchicine, but data pertaining to predictors of success were not provided. The aims of our study are to describe a cohort of pediatric patients with FMF who discontinued colchicine therapy, and to identify factors predicting successful termination of colchicine. Methods This study describes a cohort of pediatric patients with FMF who discontinued colchicine therapy following a relatively prolonged attack-free period (≥6 month), and identifies factors predicting successful termination. Data collected included demographic, clinical, and laboratory characteristics of children diagnosed with FMF < 16 years who underwent a trial of colchicine discontinuation. Data from patients who successfully ceased colchicine therapy were compared to that of patients who relapsed. Results Of 571 patients with FMF, 59 (10.3%) discontinued colchicine therapy. The average attack-free period before enrollment was 1.4±0.97 years. Follow-up after ceasing colchicine was 5.0±3.05 years during which time 11 (20%) patients had an attack. The most common symptoms were fever (92%) and abdominal pain (84.6%). For those failing discontinuation, colchicine was restarted within 1.3 years (range: 0.3-5.0; median 0.7 years). A longer attack-free period prior to colchicine discontinuation predicted success. Myalgia and arthritis prior to colchicine cessation were more common among children who required renewal of colchicine. Conclusion Cessation of colchicine therapy should be considered following prolonged remission in a select group of patients. Patients with arthritis or myalgia are more likely to have an attack after ceasing colchicine therapy.

Case of familial mediterranean fever presenting with constant abdominal pain

2016 ◽  
Vol 12 (5) ◽  
pp. 299-300
Author(s):  
İhsan Ateş ◽  
Ömer Akca ◽  
İskender Bülbül ◽  
Nisbet Yilmaz
Keyword(s):  
Abdominal Pain ◽  
Familial Mediterranean Fever ◽  
Mediterranean Fever

scholarly journals A case of familial Mediterranean fever who complained of periodic fever and abdominal pain diagnosed by MEFV gene analysis

2016 ◽  
Vol 39 (1) ◽  
pp. 72-77
Author(s):  
Chie OGITA ◽  
Kiyoshi MATSUI ◽  
Dai KISIDA ◽  
Mariko KAKUDOU ◽  
Masahide YAZAKI ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Familial Mediterranean Fever ◽  
Periodic Fever ◽  
Gene Analysis ◽  
Mediterranean Fever ◽  
I Gene
Sign in / Sign up

Export Citation Format

Share Document